Overview of Vercef (cefaclor)

Quick Facts

Property	Description
Active Ingredient	Cefaclor
Form	Oral Capsule, Extended-Release Tablet, Oral Suspension
Pharmacological Class	Antibiotic, Second-Generation Cephalosporin
General Purpose	Eliminate susceptible bacterial infections
Origin	Semisynthetic

Vercef is a prescription medicine containing the active compound Cefaclor, which is classified as an antibiotic used to manage susceptible bacterial infections. Cefaclor belongs to the cephalosporin family, a specific group of β-lactam antimicrobials.

Vercef (Cefaclor): Identity and Pharmacological Class

Cefaclor is categorized as a semisynthetic compound and is officially classified as a second-generation cephalosporin. Cefaclor is a key member of the cephalosporin group, with a primary therapeutic use against bacterial infections.

As a second-generation agent, Cefaclor is clinically recognized for its improved stability and expanded spectrum compared to earlier cephalosporins, targeting specific Gram-negative bacteria while maintaining effectiveness against many Gram-positive organisms. The brand Vercef is one trade name under which Cefaclor is marketed, often specifically formulated for pediatric use when provided as an oral suspension.

General Purpose and Action of Cefaclor

The primary general purpose of Cefaclor is to achieve the bactericidal (bacteria-killing) elimination of the pathogenic organisms responsible for the infection.

Cefaclor operates as a potent inhibitor of the final steps of bacterial cell-wall synthesis. This clarifies that the medicine works fundamentally by preventing the bacteria from maintaining their protective structure. A typical use scenario involves eliminating bacteria responsible for common conditions, such as otitis media (middle ear infections).

Composition and Available Forms

Cefaclor is a single-ingredient product formulated for oral administration. The active substance is Cefaclor (often as the monohydrate form), compounded with excipients. The medicine is commonly provided in multiple forms, including standard capsules, specialized extended-release tablets for less frequent dosing, and a powder for oral suspension that is mixed before use. The availability of Vercef in an oral suspension is a key differentiating feature that facilitates its use in children and infants, a target patient group.

Regulatory References

What side effects are possible with Vercef (cefaclor)?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Cefaclor as officially documented in government regulatory sources, such as the FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).

Cefaclor is categorized by the potential for adverse reactions affecting multiple physiological systems. The most Common events, occurring in the gastrointestinal system, include diarrhea, nausea, and vomiting. Other frequently listed effects fall under Infections and Infestations, such as candidiasis or vaginitis, which are considered superinfections associated with antibiotic use. Effects classified as Uncommon include headache, dizziness, and transient changes in blood parameters like eosinophilia and increases in liver enzymes (AST and ALT).

Serious Adverse Reactions are explicitly documented by regulatory authorities, though these are classified as Rare or Very Rare. These include acute, severe allergic reactions such as Anaphylaxis, severe skin disorders like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and severe gastrointestinal inflammation known as Pseudomembranous Colitis.

Official Safety Constraints

The medicine is formally contraindicated for use in individuals with a known hypersensitivity to the cephalosporin class of antibiotics. Due to documented cross-sensitivity, caution is also required for patients with a history of severe immediate allergic reactions to any beta-lactam antibiotic (such as penicillin). Specific safety considerations are noted for patients with impaired renal function, where close monitoring or dose adjustment may be necessary, and for patients with a history of colitis due to the risk of C. difficile-associated diarrhea.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Cefaclor (Vercef) establishes specific risks and required emergency actions related to overdosage. The presentation of an overdose is primarily defined by two tiers of risk: common gastrointestinal symptoms and severe systemic events.

Documented Overdose Manifestations

Overdose presentations are generally non-specific and typically affect the gastrointestinal system. Officially documented signs include nausea, vomiting, diarrhea, and epigastric distress or stomach pain. These effects form the first tier of the official overdose profile.

Severe Systemic Risk and Emergency Action

Regulatory guidance identifies the potential for severe outcomes. Seizures (convulsions) are a recognized risk associated with excessive exposure to cephalosporins, particularly in patients with existing renal impairment. Immediate emergency medical attention is required upon observing any severe manifestation. The official documentation mandates that emergency services must be called immediately if the person has collapsed, experienced a seizure, has trouble breathing, or can't be awakened. Further action includes contacting the poison control helpline.

Management Procedures

Treatment for overdosage is primarily supportive. Procedural steps documented in the labeling for medical professionals may include gastric lavage if a large amount of the medicine was ingested. If seizures occur, medical professionals may administer anticonvulsant therapy. Hemodialysis is also noted as a procedure that can shorten the serum half-life of Cefaclor.

Therapeutic Uses of Vercef (cefaclor)

Vercef (cefaclor) is commonly used to help with acute or disruptive episodes caused by susceptible bacterial infections across several key organ systems. By addressing the underlying bacterial cause, it provides support that helps ease the overall symptom burden and supports the patient during difficult episodes by easing distress during symptomatic periods.

Management of Symptomatic Discomfort

The medication is applied across domains where additional symptomatic support is needed, relevant in conditions presenting with acute episodes of respiratory tract infections, including otitis media, pharyngitis, tonsillitis, and bacterial pneumonia; conditions involving infections of the skin and skin structure; and conditions where functional stability becomes affected, such as urinary tract infections like cystitis and pyelonephritis.

This application is relevant for managing symptoms that interfere with daily comfort in situations where patients experience acute manifestations, such as fever, sore throat, redness in the skin, and painful urination. It assists with maintaining functional stability when symptoms become more noticeable.

Quick Fact: Support for Symptomatic Discomfort

Property	Description
Primary Symptom Domain	Symptoms related to inflammatory or irritative states
Context of Use	Applied in clinical settings that involve acute or unstable symptom patterns
Patient Benefit	Contributes to improved comfort during periods of heightened symptoms

Regulatory References

Cefaclor: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Vercef (cefaclor)?

The eligibility for Cefaclor use is determined by governmental regulatory bodies based on known allergic risk, age, and pre-existing medical conditions.

Eligibility scope	Official Regulatory Status (Strictly Label-Based)
Populations for whom use is contraindicated	Patients with known hypersensitivity to Cefaclor or to the entire cephalosporin class of antibiotics.
Age-related eligibility rules	Use is established in children ge 1 month of age and in adults. Safety and efficacy are not established for use in infants under one month of age.
Condition-specific eligibility rules	Caution is required for patients with marked renal impairment and those with a history of gastrointestinal disease, particularly colitis.
Pregnancy and lactation eligibility status	Pregnancy: Category B (US FDA); use is recommended only if clearly needed. Lactation: Cefaclor is excreted in human milk in low concentrations, and use requires official caution.

The official drug label dictates that use is absolutely prohibited for individuals with an allergy to this class of antibiotics. Other populations, such as those with severely reduced kidney function or a history of colitis, are subject to conditional eligibility, requiring specific caution. The medicine's use is not established in infants under one month of age, serving as a primary age exclusion criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Vercef (cefaclor) based on changes in systemic exposure, effects on other medicinal products, and interference with absorption.

Category	Documented Interaction Statement
Exposure-Altering Agents	Probenecid inhibits the renal tubular secretion of Cefaclor, a process that leads to increased and prolonged serum concentrations of the antibiotic.
Anticoagulants	Co-administration with Warfarin may result in increased prothrombin time with or without clinical bleeding, indicating a potential pharmacodynamic interaction.
Absorption Interference	Aluminum- and Magnesium-containing Antacids diminish the absorption of Cefaclor extended-release tablets; administration must be separated by at least one hour.
Food Interaction	Taking Cefaclor with food does not change the total amount absorbed but reduces the peak plasma concentration (Cmax) by 50% to 75%.
Laboratory Test Interference	Cefaclor administration may result in a false-positive reaction for glucose in urine tests that use copper sulfate reagents, such as Benedict’s or Fehling’s solutions.

Regulatory information notes that Cefaclor's half-life is only slightly prolonged in patients with reduced renal function, and official prescribing information states that dosage adjustments for moderate to severe renal impairment are usually not required. Additionally, a theoretical potential for antagonism exists with bacteriostatic antibacterial agents.

Mechanism of Action

Irreversible Inhibition of Bacterial Cell Wall Assembly

Cefaclor's action is bactericidal, stemming from its role as an irreversible inhibitor of key bacterial enzymes. The drug targets Penicillin-Binding Proteins (PBPs), which are transpeptidases crucial for the final cross-linking of the peptidoglycan polymer that forms the rigid bacterial cell wall. By covalently binding to these PBPs, Cefaclor permanently halts the cell wall construction process, initiating a mechanistic cascade.

Causal Cascade Leading to Microbial Cell Lysis

The blockade of peptidoglycan synthesis results in a structurally weak and compromised bacterial cell wall, which is unable to withstand the high internal osmotic pressure of the bacterium. This failure triggers the activation of bacterial autolytic enzymes, causing the cell to rupture (lyse) and die. This systematic destruction and elimination of the susceptible pathogen population is the physiological consequence that defines the drug's mechanism-based activity.

Constraints and Limits to Mechanistic Efficacy

The efficacy of the Cefaclor mechanism is biologically limited by specific bacterial resistance strategies. This includes the production of beta-lactamase enzymes, which enzymatically destroy the drug before it can bind to PBPs, and structural modifications to the PBPs themselves, which reduce the binding affinity for Cefaclor. These constraints prevent the drug's inhibitory action from being fully realized in resistant strains.

Dosage and Administration Information

Administration and Dosing Principles

Cefaclor is administered exclusively by the oral route, available as capsules, extended-release tablets, and a powder for oral suspension. The general principle of usage involves dividing the total daily dose into scheduled intervals.

For adults, the typical dosage for the immediate-release form is 250 mg every 8 hours, although this may be increased to 500 mg every 8 hours for more severe contexts, with a maximum of 4 g (4000 mg) per day. The extended-release tablets are generally administered twice daily (every 12 hours).

Pediatric administration is based on body weight, typically 20 mg/kg/day in divided doses, with the option to increase to 40 mg/kg/day for serious infections, not to exceed 1 g daily. Safety and efficacy have not been established for infants less than one month old.

Administration Conditions and Duration

Administration is subject to specific conditions related to food and form. The immediate-release forms may be taken with or without food, while the extended-release tablets must be administered with meals to ensure optimal absorption. Extended-release tablets must not be crushed, cut, or chewed.

Treatment duration is typically continued for a minimum of 48 to 72 hours after clinical evidence of bacterial eradication is achieved. However, for infections caused by Group A beta-haemolytic streptococci, the course is at least 10 full days.

Recent Clinical Evidence

Evidence for Use in Acute Otitis Media and Throat Infections

The research exploring cefaclor for common infections like Acute Otitis Media (AOM) and throat infections relies primarily on short-term Randomized Controlled Trials (RCTs) involving pediatric patients. Studies monitored bacteriological outcomes and clinical outcomes (changes in fever or pain scores). Trials reported patterns in bacteriological eradication rates, though certainty remains low regarding the full range of long-term effects. There is limited information for outcomes such as sustained hearing status beyond the defined follow-up durations.

Evidence for Use in Respiratory Tract Infections

Research for Lower Respiratory Tract Infections (LRTIs), including pneumonia and chronic bronchitis flare-ups, utilized open-label studies and retrospective analyses, primarily in adult populations. Studies monitored microbiological status and clinical response (a physician-assessed measure of the patient's status). Long-term effects are not fully established for these chronic conditions, and evidence is limited due to short follow-up durations in many trials.

Evidence for Use in Skin and Urinary Tract Infections

Cefaclor was studied for uncomplicated Urinary Tract Infections (UTIs) and Skin and Skin Structure Infections (SSSI) using comparative trials. Researchers monitored clinical and bacteriological status, tracking recurrence for several weeks post-therapy for UTIs. Comparative evidence is lacking against other contemporary agents for use in high-recurrence populations, and the evidence quality varies across studies.

Long-Term Studies and Key Study Populations

Clinical trials generally focus on short-term status monitoring. The overall evidence contributes to understanding acute symptom patterns but is limited regarding long-term outcomes. The core clinical research was primarily evaluated in specific groups, including children and infants and adults for acute conditions. Data for certain comorbid groups, such as those with impaired organ function, remain insufficient or uncertain.

Gaps in the Research: What Remains Uncertain

The follow-up durations were limited in many pivotal trials, meaning long-term effects are not fully established. The research applies only to the populations studied. Comparative evidence is lacking for some of the newer, shorter-course antibiotic regimens now used in clinical practice, highlighting an area where more targeted research is needed.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Vercef (cefaclor) (FAQ)

Q: What is the main difference between Vercef (cefaclor) and penicillin?

Cefaclor is classified as a second-generation cephalosporin, which is chemically related to the penicillin class of antibiotics. Regulatory documents state that cross-hypersensitivity has been documented among beta-lactam antibiotics, which includes both cephalosporins and penicillins. Therefore, individuals with a known severe allergy to penicillin are subject to specific safety considerations.

Q: Is Vercef (cefaclor) considered a broad-spectrum or narrow-spectrum antibiotic?

Based on its profile of activity, Cefaclor is recognized as having an expanded spectrum of activity. Official product information defines the drug as having activity against a range of both Gram-negative and Gram-positive bacteria, which supports its classification as a second-generation agent with an expanded spectrum compared to earlier cephalosporins.

Q: Is Vercef the same medication as Ceclor or Raniclor?

Yes, Cefaclor is the single active compound present in these and other various brand-name medications. Vercef, Ceclor, and Raniclor are all trade names under which the active ingredient Cefaclor is marketed and sold. They all contain the same core therapeutic substance.

Q: Why does taking Vercef (cefaclor) sometimes cause a yeast infection or thrush?

Antibacterial medications like Cefaclor are only effective against bacterial infections, but they can also affect normal microbial balance in the body. According to regulatory documents, prolonged use of Cefaclor may sometimes result in the overgrowth of nonsusceptible organisms (known as superinfection). This is the accepted cause for infections such as candidiasis (yeast infection or thrush).

Q: Is it typical to experience diarrhea a few weeks after stopping Vercef (cefaclor)?

Diarrhea is a known side effect of many antibiotics, but a more serious condition, C. difficile-associated diarrhea (CDAD), has been reported with Cefaclor. Official warnings state that watery and bloody stools related to CDAD can occur as late as two or more months after the final dose.

Q: What are the main differences between Cefaclor and Cephalexin (Keflex)?

Cefaclor is categorized as a second-generation cephalosporin, while Cephalexin (Keflex) is a first-generation cephalosporin. This classification difference relates to the spectrum of bacteria each drug is designed to target, with second-generation agents typically having broader coverage against certain bacteria.

Q: What are the specific signs of a severe gut infection, like C. diff, related to Vercef (cefaclor)?

A severe gut infection, known as C. difficile-associated diarrhea (CDAD), is a serious adverse reaction noted in the warnings section of the drug label. Symptoms of this condition can include severe, watery and bloody stools, accompanied by stomach cramps and fever. These signs are associated with a serious condition and should be addressed promptly by a healthcare professional.

Q: Can Vercef (cefaclor) be used to treat infections caused by a virus?

Official regulatory information indicates that antibacterial drugs like Cefaclor are intended exclusively for treating bacterial infections. They are not indicated for, and do not work against, viral infections, such as the common cold or flu.

Q: How quickly does Vercef (cefaclor) usually start to show an effect on an infection?

Clinical pharmacology information indicates that average peak serum concentrations—the point when the drug level in the blood is highest—is generally achieved within 30 to 60 minutes following oral administration in fasting subjects.

Q: Can Vercef (cefaclor) affect the effectiveness of birth control pills?

Official drug information from the NIH states that Cefaclor may potentially decrease the effectiveness of hormonal contraceptives. This warning applies to various forms of hormonal contraceptives, including pills and other delivery methods.

Q: Does Vercef (cefaclor) interact with common over-the-counter pain relievers?

Drug interaction reports indicate that Cefaclor may have potential interactions with certain common pain relievers, such as aspirin and acetaminophen (paracetamol). These potential interactions may require observation by a healthcare professional.

Q: What are the signs of a serious allergic reaction to Vercef (cefaclor)?

Serious acute allergic reactions, such as anaphylaxis, are serious adverse reactions that indicate the need for prompt emergency medical assistance. The warning section of the official label states these may be characterized by symptoms such as hives, swelling of the face and throat, or difficulty breathing.

Q: Can Vercef (cefaclor) cause a skin rash that looks like hives?

Hypersensitivity reactions are listed in the official adverse reactions section. Skin reactions such as morbilliform eruptions and urticaria (hives) have been reported in patients taking Cefaclor.

Q: What is a serum sickness-like reaction, and is it a known risk with Vercef (cefaclor)?

The official adverse reactions section notes that serum sickness-like reactions have been reported with Cefaclor. These are characterized by rash, joint symptoms (arthritis or joint pain), with or without fever, and usually subside within a few days after stopping the drug.

Q: Can Vercef (cefaclor) cause joint pain or temporary arthritis?

Joint symptoms, specifically described as arthritis (joint inflammation) or arthralgia (joint pain), are a characteristic feature of the reported serum sickness-like reactions noted in official documents.

Q: Is it common for antibiotics like Vercef (cefaclor) to cause insomnia or agitation?

Central nervous system (CNS) effects have been reported rarely in patients taking Cefaclor. Regulatory adverse reaction reports list both insomnia and agitation as effects where a causal relationship remains uncertain.

Q: Is it safe to drive or operate machinery while taking Vercef (cefaclor)?

Adverse reactions reported in regulatory documents include central nervous system effects such as dizziness and confusion. Due to the potential for these effects, patients are advised to be aware of their personal response before engaging in activities that require full mental alertness, such as driving or operating machinery.

Q: Does the liquid suspension form of Vercef (cefaclor) contain sugar that might affect diabetic patients?

According to the official DailyMed listing of inactive ingredients, the oral suspension formulation of Cefaclor includes sucrose (a form of sugar). The presence of sucrose is a required piece of information for patients monitoring their sugar intake.

Q: Why do some people report feeling unusually tired or weak while on Vercef (cefaclor)?

Official adverse reaction reports for Cefaclor list somnolence (drowsiness or sleepiness) as a rare central nervous system effect. As with other rare reactions, a causal relationship between the drug and somnolence is noted as uncertain.

Q: What is the likelihood of having reversible hyperactivity as a side effect?

Reversible hyperactivity is one of the central nervous system effects that has been reported rarely in official documents. As a rare adverse reaction, the likelihood of this occurring is low, and the causal relationship is noted as uncertain.

Q: Is it normal to have a slight fever or chills after starting Vercef (cefaclor)?

While fever is not listed as a common, isolated side effect, it is noted as a possible component of certain generalized hypersensitivity reactions. Official adverse event reports indicate that fever may accompany the rash and joint symptoms seen in a serum sickness-like reaction.

How should Vercef (cefaclor) be stored and disposed of?

How to Store and Dispose of Vercef (Cefaclor)

Storage requirements for Cefaclor are defined by the product form to ensure stability. Dry formulations, including capsules, extended-release tablets, and the unmixed powder, must be stored at Controlled Room Temperature, typically 20^circ to 25^circC (68^circ to 77^circF), away from light and excess moisture. The container must be kept tightly closed and out of the sight and reach of children.

Reconstituted Suspension Stability

Once the powder is mixed, the liquid suspension must be stored in a refrigerator at 2^circ to 8^circC (36^circ to 46^circF) and must not be frozen. The liquid is stable for only 14 days under refrigeration, after which any unused portion must be discarded.

Disposal Instructions

To dispose of unused or expired Cefaclor, utilize an authorized drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed bag before disposal in the household trash.

Vercef (cefaclor)